Trinity Biotech plc (NASDAQ:TRIB) Q4 2023 Earnings Call Transcript

What we’re really doing is looking to tweak that, change the form factor, improve the manufacturing process as an experienced high-scale medical device manufacturer ourselves. You know we’re confident we can do that. So that’s not a built-in ongoing drain on cash resources. We will only continue to invest in that business Paul, while we are very confident that we will see returns in that. And my own personal view would be we’ll see very, very significant returns on any investment in that area.

Paul Nouri: Okay. Thanks a lot.

Operator: Thank you. At this time, we’ve reached the end of our allotted time for question-and-answer sessions today, and that will also conclude today’s conference. Thank you for your participation and have a wonderful day.

John Gillard: Thank you, everybody.